Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Lessened by State Street Corp

State Street Corp lowered its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 2.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 899,379 shares of the company’s stock after selling 26,260 shares during the quarter. State Street Corp owned approximately 2.36% of Tarsus Pharmaceuticals worth $29,581,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC raised its holdings in shares of Tarsus Pharmaceuticals by 16.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 210,531 shares of the company’s stock valued at $6,924,000 after purchasing an additional 29,465 shares in the last quarter. Creative Planning bought a new stake in Tarsus Pharmaceuticals in the 3rd quarter valued at $362,000. Vestal Point Capital LP bought a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter worth about $7,565,000. Essex Investment Management Co. LLC bought a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter worth about $3,590,000. Finally, Assenagon Asset Management S.A. increased its stake in Tarsus Pharmaceuticals by 7.3% in the third quarter. Assenagon Asset Management S.A. now owns 1,141,247 shares of the company’s stock valued at $37,536,000 after acquiring an additional 77,825 shares during the period. Institutional investors own 90.01% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on TARS shares. The Goldman Sachs Group upped their price objective on Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Oppenheimer boosted their target price on shares of Tarsus Pharmaceuticals from $63.00 to $65.00 and gave the company an “outperform” rating in a research note on Thursday, November 14th. Finally, William Blair raised shares of Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. One investment analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $54.20.

Tarsus Pharmaceuticals Price Performance

Tarsus Pharmaceuticals stock opened at $52.91 on Friday. The firm has a market capitalization of $2.02 billion, a P/E ratio of -13.89 and a beta of 1.04. The business has a 50-day moving average of $46.51 and a 200-day moving average of $35.02. The company has a current ratio of 5.42, a quick ratio of 5.38 and a debt-to-equity ratio of 0.30. Tarsus Pharmaceuticals, Inc. has a 1 year low of $18.99 and a 1 year high of $56.77.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.